Pharma stocks under pressure: Sun Pharma cracks 5%, Nifty Pharma down 2% after Trump’s big blow on US drug pricing
Pharma stocks under pressure: Sun Pharma cracks 5%, Nifty Pharma tumbles after Trump’s shocker on.
)
11:04 AM IST
Indian pharma stocks tanked in early trade on Monday, May 12, after US President Donald Trump announced an executive order to slash prescription drug prices in the United States by 30 to 80 per cent. This sent shockwaves across the pharmaceutical sector, especially among Indian companies heavily exposed to the US generics market.
At 9:30 AM, the NIFTY Pharma index was down 1.98 per cent to 20,653.80, with leading pharmaceutical names like Sun Pharma, Lupin, Dr Reddy’s, and Aurobindo Pharma witnessing sharp declines.
Sun Pharma leads pharma selloff
Sun Pharma is the worst-hit, plunging over 5 per cent in early trade. The company has significant exposure to the US generics and dermatology markets through its subsidiary Taro Pharma, making it highly vulnerable to any pricing reforms in the US.
Lupin also saw losses in early trade of over 2.5 per cent. The US remains Lupin’s largest market, contributing 36.2 per cent to its total revenue for the first nine months of FY24. Other stocks include Aurobindo Pharma (-2.12%), Divi's Labs (-1.17%), and Glenmark Pharma (-1%).
Trump’s executive order shocks markets
On his Truth Social platform, Trump wrote:“Prescription drug prices in the US are five to ten times higher than other nations. I’m signing an executive order to cut them by 30 to 80 per cent.”
He added the ‘Most Favoured Nation’ policy would ensure the US pays the same price as the country with the lowest price globally—raising serious implications for Indian pharma exports.
Pharma outlook: Weakness likely to continue
The Nifty Pharma index has already declined over 10 per cent so far in 2025, and today’s fall extends the pain. While some stocks like Cipla and SPARC manages to stay marginally in the green, overall sentiment remains bearish as of yet.
Analysts expect continued volatility in pharma counters as more details on the US pricing policy emerge. Indian drugmakers will likely face pressure on margins, especially those with high dependence on the US generics market.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
)
)
)
)
)
)
)
)
)
Anil Singhvi views Trump's executive order to slash US drug prices as negative for Indian pharma 
US-China Trade Truce Stuns Street: What it means for IT, pharma, and your portfolio
Trump’s pharma order spooks Indian drug makers; Anil Singhvi expects one stock to lead rebound
Nifty Pharma plunges 6% as US tariff fears hammer exports; Gland Pharma, Divi's Labs tumble 11%
Trump tariffs trigger 33% crash in these stocks in February: Is the worst behind?
